Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Cymabay Therapeutics (CBAY)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 708,750
  • Shares Outstanding, K 58,720
  • Annual Sales, $ 10,000 K
  • Annual Income, $ -27,560 K
  • 36-Month Beta 2.06
  • Price/Sales 72.22
  • Price/Cash Flow N/A
  • Price/Book 8.03

Price Performance

See More
Period Period Low Period High Performance
1-Month
10.50 +16.00%
on 04/04/18
15.00 -18.80%
on 04/11/18
+0.03 (+0.25%)
since 03/23/18
3-Month
10.50 +16.00%
on 04/04/18
15.59 -21.87%
on 03/05/18
+0.34 (+2.87%)
since 01/25/18
52-Week
3.16 +285.44%
on 04/27/17
15.59 -21.87%
on 03/05/18
+8.62 (+242.13%)
since 04/25/17

Most Recent Stories

More News
Aptose Announces Appointment of Caroline M. Loewy to Board of Directors

Aptose Biosciences Inc. (NASDAQ:APTO) (TSX:APS), a clinical-stage company developing highly differentiated therapeutics targeting the underlying mechanisms of cancer, today announced the appointment of...

CORT : 16.80 (-3.11%)
APTO : 3.34 (+5.03%)
CBAY : 12.16 (+0.75%)
TBRA : 42.09 (+0.65%)
APS.TO : 4.28 (+4.39%)
ACHV : 1.33 (unch)
Report: Developing Opportunities within CymaBay Therapeutics, IAC/InterActiveCorp, Axcelis Technologies, La Quinta, Hornbeck Offshore Services, and Sprouts Farmers Market -- Future Expectations, Projections Moving into 2018

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of CymaBay Therapeutics Inc. (NASDAQ:CBAY),...

LQ : 19.82 (+1.07%)
ACLS : 22.15 (-1.12%)
CBAY : 12.16 (+0.75%)
IAC : 155.82 (-1.06%)
SFM : 24.58 (+0.57%)
HOS : 3.73 (+2.47%)
Companies that Stand to Benefit from the Biotech Market Bottoming

FN Media Group Presents Microcapspeculators.com News Commentary

SRNE : 6.10 (+0.83%)
CELG : 89.06 (-0.09%)
CBAY : 12.16 (+0.75%)
ECYT : 9.02 (+0.45%)
PPCB : 0.0660 (+3.13%)
CymaBay Therapeutics (CBAY) in Focus: Stock Moves 11.4% Higher

CymaBay Therapeutics (CBAY) was a big mover last session, as the company saw its shares rise more than 11% on the day.

CBAY : 12.16 (+0.75%)
CORI : 9.96 (-0.80%)
CymaBay Announces Positive New 12-Week and 26-Week Results from its Ongoing Phase 2 Study of Seladelpar in Patients with Primary Biliary Cholangitis at The International Liver Congress(TM) 2018

-- Seladelpar maintains potent anti-cholestatic and anti-inflammatory activity and appears safe and well tolerated, with no drug-induced pruritus, through 26 weeks of treatment

CBAY : 12.16 (+0.75%)
Biotech Stocks' Research Reports Released on CorMedix, Curis, Cyclacel Pharma, and Cymabay Therapeutics

WallStEquities.com strives to bring the best free research to the investment community. Today we are offering reports on CRMD, CRIS, CYCC, and CBAY which can be accessed for free by signing up to www.wallstequities.com/registration....

CRIS : 0.54 (+1.89%)
CBAY : 12.16 (+0.75%)
CRMD : 0.20 (unch)
CYCC : 1.38 (+2.22%)
CymaBay Reports Fourth Quarter and Fiscal 2017 Financial Results and Provides Corporate Update

Conference call and webcast today at 4:30p.m. ET

CBAY : 12.16 (+0.75%)
Consolidated Research: 2018 Summary Expectations for Sunrun, CymaBay Therapeutics, Arrow Electronics, MGM Resorts International, Celanese, and Motorola Solutions -- Fundamental Analysis, Key Performance Indications

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Sunrun Inc. (NASDAQ:RUN), CymaBay...

MGM : 35.29 (-0.65%)
CE : 109.82 (+0.42%)
MSI : 109.18 (-0.42%)
ARW : 76.05 (+0.61%)
CBAY : 12.16 (+0.75%)
RUN : 9.01 (+1.46%)
Technical Perspectives on Biotech Stocks -- CorMedix, Curis, Cyclacel Pharma, and Cymabay Therapeutics

WallStEquities.com strives to bring the best free research to the investment community. Today we are offering reports on CRMD, CRIS, CYCC, and CBAY which can be accessed for free by signing up to www.wallstequities.com/registration....

CRIS : 0.54 (+1.89%)
CBAY : 12.16 (+0.75%)
CRMD : 0.20 (unch)
CYCC : 1.38 (+2.22%)
CymaBay Therapeutics to Participate in Investor Conferences in February

CymaBay Therapeutics, Inc. (Nasdaq:CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that management...

CBAY : 12.16 (+0.75%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 32% Sell with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak.

See More Share

Business Summary

CymaBay Therapeutics Inc. is a biopharmaceutical company. It is focused on the development and commercialization of proprietary new medicines for important human diseases. The Company's lead product candidate, arhalofenate, is being developed for the treatment of gout. CymaBay Therapeutics Inc. is based...

See More

Key Turning Points

2nd Resistance Point 13.05
1st Resistance Point 12.56
Last Price 12.16
1st Support Level 11.72
2nd Support Level 11.37

See More

52-Week High 15.59
Last Price 12.16
Fibonacci 61.8% 10.84
Fibonacci 50% 9.38
Fibonacci 38.2% 7.91
52-Week Low 3.16

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.

Free Barchart Webinar